Literature DB >> 15488607

Neopterin in HIV-1 infection.

Barbara Wirleitner1, Katharina Schroecksnadel, Christiana Winkler, Dietmar Fuchs.   

Abstract

Neopterin is well established as a reliable marker in HIV-1 infection. Neopterin concentrations measured in urine or serum indicate sensitively the course and progression of the disease as well as efficacy of anti-retroviral therapy. The main trigger for neopterin production is Th1-type cytokine interferon-gamma. During acute HIV-1 infection, enhanced formation of neopterin occurs already at a very early time point, before antibody seroconversion takes place. After this stage, neopterin concentrations in serum and urine closely correlate with virus load in the circulation of HIV-1-infected patients. Data provide evidence for an important role of immune activation and Th1-type cytokine interferon-gamma in the pathogenesis of HIV-1 infection. This review subsumes the importance of neopterin as a marker in HIV-1 infection. Further evidence is increasing, that neopterin derivatives might modulate immune response by interfering with the cellular redox balance, activating redox-sensitive transcription factors, or inducing apoptosis in specific cell types. The possible impact of neopterin derivatives and of other biochemical pathways induced by interferon-gamma such as indoleamine 2,3-dioxygenase in chronic diseases like HIV-1 infection is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15488607     DOI: 10.1016/j.molimm.2004.06.017

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  29 in total

1.  Using novel methods to examine stress among HIV-positive African American men who have sex with men and women.

Authors:  Dorie A Glover; John K Williams; Kimberly A Kisler
Journal:  J Behav Med       Date:  2012-04-27

2.  Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy.

Authors:  Adriana A Byrnes; David M Harris; Sowsan F Atabani; Beulah P Sabundayo; Susan J Langan; Joseph B Margolick; Christopher L Karp
Journal:  J Leukoc Biol       Date:  2008-09-19       Impact factor: 4.962

3.  Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.

Authors:  Michael J Peluso; Francesca Ferretti; Julia Peterson; Evelyn Lee; Dietmar Fuchs; Antonio Boschini; Magnus Gisslén; Nancy Angoff; Richard W Price; Paola Cinque; Serena Spudich
Journal:  AIDS       Date:  2012-09-10       Impact factor: 4.177

Review 4.  CNS Persistence of HIV-1 in Children: the Untapped Reservoir.

Authors:  Ann Chahroudi; Thor A Wagner; Deborah Persaud
Journal:  Curr HIV/AIDS Rep       Date:  2018-10       Impact factor: 5.071

5.  A non-specific biomarker of disease activity in HIV/AIDS patients from resource-limited environments.

Authors:  Priyesh Bipath; Peter Levay; Steve Olorunju; Margaretha Viljoen
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

6.  Association of IL-12+ DC with High CD3+CD4-DR+ lymphocyte counts in long-term HIV-infected hemophilia patients with clinically stable disease.

Authors:  Volker Daniel; Cord Naujokat; Mahmoud Sadeghi; Rainer Zimmermann; Angela Huth-Kühne; Gerhard Opelz
Journal:  J Clin Immunol       Date:  2007-09-19       Impact factor: 8.317

7.  Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.

Authors:  J C Probasco; S S Spudich; J Critchfield; E Lee; N Lollo; S G Deeks; R W Price
Journal:  Neurology       Date:  2008-08-12       Impact factor: 9.910

8.  Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Authors:  Aylin Yilmaz; Richard W Price; Serena Spudich; Dietmar Fuchs; Lars Hagberg; Magnus Gisslén
Journal:  J Acquir Immune Defic Syndr       Date:  2008-02-01       Impact factor: 3.731

9.  Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.

Authors:  Elizabeth Sinclair; Rollie Ronquillo; Nicole Lollo; Steven G Deeks; Peter Hunt; Constantin T Yiannoutsos; Serena Spudich; Richard W Price
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

Review 10.  Inflammaging as a prodrome to Alzheimer's disease.

Authors:  Brian Giunta; Francisco Fernandez; William V Nikolic; Demian Obregon; Elona Rrapo; Terrence Town; Jun Tan
Journal:  J Neuroinflammation       Date:  2008-11-11       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.